RxDoctor Payments Data

Reed Shnider, MD

Cardiovascular Disease · Olney, MDNPI 1265449045

Payments from drug & device makers

$1,418in general payments, 2019–2025

Across 71 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$253
  • Merck$181
  • Amgen$144
  • AstraZeneca$135
  • Novartis$100
  • Lexicon Pharmaceuticals, Inc.$90
  • plus $514 from 12 others

What the payments were for

  • Food & beverage$1,39698%
  • Education$222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,418 in reported general payments places this provider in the 45th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$466,681
Medicare patients
1,970
Services billed
5,151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban346$480,450
Repatha SureclickEvolocumab68$94,475
XareltoRivaroxaban68$93,528
EntrestoSacubitril/Valsartan56$73,681
Repatha SyringeEvolocumab25$31,743
JardianceEmpagliflozin12$18,523
Rosuvastatin Calcium543$12,538
Ezetimibe265$11,569
Nebivolol Hcl105$10,804
VascepaIcosapent Ethyl13$10,045
Atorvastatin Calcium535$7,782
Metoprolol Succinate330$7,702
Losartan Potassium244$3,671
Pravastatin Sodium146$3,258
Ranolazine ErRanolazine23$3,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$50$480,450346 claims
Johnson & JohnsonXarelto$78$93,52868 claims
NovartisEntresto$100$73,68156 claims
Boehringer IngelheimJardiance$24$18,52312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Olney

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →